Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026)
Nurix Therapeutics' (NRIX) quarterly Income from Continuing Operations came in at 89535000.0 in Q2 2026, down 106.0% year-on-year from 1492730817.03 in Q2 2025, and down 1.8% on a QoQ basis from 87949000.0 in Q1 2026.
Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 8 years of Income from Continuing Operations data on file, last reported at 89535000.0 in Q2 2026.
- On a quarterly basis, Income from Continuing Operations fell 106.0% year-over-year to 89535000.0 in Q2 2026; TTM through May 2026 was 342126000.0, a 65.02% decrease from a year earlier, with the FY2025 full-year figure at 264457000.0, down 36.62% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 89535000.0, down from 87949000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for NRIX reached as high as 24277000.0 in Q2 2023 and fell as low as 89535000.0 in Q2 2026.
- Historically, Income from Continuing Operations has averaged 53323222.22 across 5 years, with a median of 45555000.0 in 2022.
- Across the five-year window, Income from Continuing Operations soared 46.53% in 2023 and sank 106.0% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 46717000.0 in 2022, then grew by 10.19% to 41956000.0 in 2023, then sank by 39.55% to 58549000.0 in 2024, then tumbled by 33.6% to 78221000.0 in 2025, then retreated by 14.46% to 89535000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 89535000.0 in Q2 2026, 87949000.0 in Q1 2026, and 78221000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Nurix Therapeutics | 2.64 Bn | 2.19 Bn | - | -89.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -89.54 Mn |
| Feb 28, 2026 | -87.95 Mn |
| Nov 30, 2025 | -78.22 Mn |
| Aug 31, 2025 | -86.42 Mn |
| May 31, 2025 | -43.46 Mn |
| Feb 28, 2025 | -56.35 Mn |
| Nov 30, 2024 | -58.55 Mn |
| Aug 31, 2024 | -48.96 Mn |
| May 31, 2024 | -44.55 Mn |
| Feb 29, 2024 | -41.52 Mn |
| Nov 30, 2023 | -41.96 Mn |
| Aug 31, 2023 | -36.98 Mn |
| May 31, 2023 | -24.28 Mn |
| Feb 28, 2023 | -40.73 Mn |
| Nov 30, 2022 | -46.72 Mn |
| Aug 31, 2022 | -45.71 Mn |
| May 31, 2022 | -45.40 Mn |
| Feb 28, 2022 | -42.53 Mn |
| Nov 30, 2021 | -37.69 Mn |
| Aug 31, 2021 | -28.86 Mn |